Nektaria Papadopoulou, Louise Wainwright, Vicky Lacey, Jane Wrigley, Jamie Wood, Sumanjeet Malhi, Louise Woolley, Jason King, Simon Jiang, and Rajendra Kumari
Hepatocellular carcinoma (HCC) is an aggressive cancer type with limited therapeutic treatment options. Immunotherapies such as checkpoint inhibitors are being evaluated in HCC, which therefore require suitable models for thorough preclinical development.
Subcutaneous syngeneic models are the common choice for preclinical checkpoint inhibitor assessment; however, orthotopic models have a more relevant tumor microenvironment and are more closely comparable to human disease.
CrownBio has therefore developed orthotopic, bioluminescent, syngeneic HCC models allowing non-invasive and real time tumor burden determination, and assessment of checkpoint inhibitors to treat HCC.